Genmab A/S (GNMSF) Financials
GNMSF Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 12.5 billion | 6.5 billion |
| March 31, 2026 | 12.4 billion | 6.7 billion |
| Dec. 31, 2025 | 12.8 billion | 7.0 billion |
| Sept. 30, 2025 | 7.0 billion | 1.3 billion |
GNMSF Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | 47.8 million | 37.0 million |
| March 31, 2026 | -2.0 million | 49.0 million |
| Dec. 31, 2025 | 289.2 million | 36.0 million |
| Sept. 30, 2025 | 534.0 million | 34.0 million |
GNMSF Net Income
Graph available only for paid members. Upgrade to see it.
| Date | Net Income |
|---|---|
| June 30, 2026 | 296.8 million |
| March 31, 2026 | 52.2 million |
| Dec. 31, 2025 | 31.1 million |
| Sept. 30, 2025 | 482.0 million |
GNMSF Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 1.5 billion | 4.8 billion | 119.6 million |
| March 31, 2026 | 1.5 billion | 4.9 billion | 125.0 million |
| Dec. 31, 2025 | 1.7 billion | 5.1 billion | 133.4 million |
| Sept. 30, 2025 | 3.4 billion | - | 142.0 million |
GNMSF Shares Outstanding
GNMSF Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 2.0 million | 449.6 million | 200.8 million | - |
| March 31, 2026 | 4.9 million | 433.3 million | 163.5 million | - |
| Dec. 31, 2025 | 13.2 million | 528.4 million | 208.9 million | - |
| Sept. 30, 2025 | 2.0 million | 357.0 million | 148.0 million | - |
GNMSF Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | 1.1 billion | 82.3 million |
| March 31, 2026 | 896.0 million | 65.0 million |
| Dec. 31, 2025 | 1.1 billion | 81.4 million |
| Sept. 30, 2025 | 1.0 billion | 58.0 million |
GNMSF
Price: $320
52 week price:
Earnings Per Share: 12.65 USD
P/E Ratio: 24.63
Exchange: PNK
Sector: Healthcare
Industry: Biotechnology
Market Capitalization: 19.4 billion